Zevas Indications/Uses

Primary hypercholesterolaemia: It is indicated as adjunctive therapy to diet to reduce elevated total cholesterol (total-C), LDL cholesterol (LDL-C), Apolipoprotein B (Apo B), non-HDL-cholesterol and triglycerides (TG) and to increase HDL cholesterol (HDL-C) in patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidemia.
Many risk factors should be considered when administering lipid-altering agents to patients with an increased risk of atherosclerotic vascular disease due to hypercholesterolemia.
Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate.
Prior to administration of this drug, other secondary causes of dyslipidemia (e.g., diabetes, hypothyroidism, obstructive liver disease, chronic renal failure, drugs that increase LDL-cholesterol and drugs that decrease HDL-cholesterol [progestin, anabolic steroid, and corticosteroid] should be checked and treated if necessary.
Lipid tests should include total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides. If the triglyceride level is more than 400 mg/dL (>4.5 mmol/L), the concentration of LDL-cholesterol should be measured by ultracentrifugation.
If hospitalized due to an acute coronary artery, lipid tests should be measured at admission or within 24 hours of admission. These measurements may be helpful in starting LDL-lowering treatment at discharge from the hospital or before.